Reported results
- Royalty revenues for the third quarter of 2026 were $171 thousand.
- Research and development expenses were $5,029 thousand for the third quarter of 2026.
- Selling, general and administrative expenses were $4,361 thousand for the third quarter of 2026.
- Net loss for the third quarter of 2026 was $8,857 thousand, or $0.12 basic and diluted net loss per common share.
- Total operating expenses were $9,390 thousand for the third quarter of 2026.
- As of September 30, 2026, Cardiff Oncology had approximately $33.8 million in cash, cash equivalents, and short-term investments.
Guidance
- The Company believes its current cash resources are sufficient to fund its operations to the end of the third quarter of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
